Literature DB >> 29156917

Advance care planning for patients with advanced neurology diseases.

Ka-Chi Cheung1, Vikki Wai-Kee Lau1, Ka-Chun Un2, Man-Sheung Wong2, Kwok-Ying Chan3.   

Abstract

BACKGROUND: Advanced neurology diseases including motor neuron disease (MND) are usually progressive life-limiting illness and could be devastating for patients, families and caregivers. Although medical technologies, such as enteral feeding and non-invasive ventilation, may prolong life expectancy of the patients, their utilization prompts important ethical questions in regard to their quality of life (QoL). Little attention had been paid on how ACP practice would practically help with patients suffering from different neurology diseases. We are unaware of any published studies on ACP practice among patients with different neurology diseases. In our study, we assessed end-of-life (EOL) care preferences, documentation, and communication in patients with various types of advanced neurology diseases.
METHODS: This was a retrospective chart review of all patients referred to the neuro-palliative care team (NPCT) in a local acute hospital in Hong Kong. The study was approved by the institutional review board of the University of Hong Kong. NPCT consultation was hand abstracted from the electronic health record if there was a subspecialty palliative care (PC) consultation note during the study period. Hand abstraction of data also included any content related to advance care planning (ACP) [advance directive (AD), resuscitation order, ventilator support, artificial feeding, patient wishes, legacy].
RESULTS: For patient who signed AD, items including cardiopulmonary resuscitation (100%), mechanical ventilation (100%), artificial nutrition and hydration (80%) were mentioned more frequently than other EOL interventions. For patients who had ACP but without AD, the most common diagnosis is bad stroke (60%). Place of death, artificial nutrition and hydration were most mentioned EOL interventions.
CONCLUSIONS: EOL decision making in patients with advanced neurology disease is often delayed. This study showed that MND patients are readier to discuss their EOL issues and signed their AD. The NPCT can play a valuable role in EOL discussions in patients with advanced neurology diseases under collaboration between the PC and the neurology teams.

Entities:  

Keywords:  Neurology; advance care planning (ACP); motor neuron disease (MND); neuro-palliative care team (NPCT); palliative

Mesh:

Year:  2017        PMID: 29156917     DOI: 10.21037/apm.2017.09.10

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  5 in total

1.  Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report.

Authors:  Chi Yan Wong; Kwok Wai Tsang; Cho Wing Li; Ho Yan Au; Kwok Ying Chan
Journal:  AME Case Rep       Date:  2021-01-25

2.  Overview of the Motivation of Advance Care Planning: A Study from a Medical Center in Taiwan.

Authors:  Yi-Jhen He; Ming-Hwai Lin; Jo-Lan Hsu; Bo-Ren Cheng; Tzeng-Ji Chen; Shinn-Jang Hwang
Journal:  Int J Environ Res Public Health       Date:  2021-01-07       Impact factor: 3.390

3.  Introducing a Supportive Care Team for Advance Directive Education in a Neurological and Neurosurgical Patient Population.

Authors:  Charlotte Henke; Emily Mroz; Ngoc Anh Le; Hannah M Gregory; Ashley Ghiaseddin; Nikolaus R McFarland; Jacqueline Baron-Lee
Journal:  J Patient Exp       Date:  2020-06-23

Review 4.  Talking about the end of life: communication patterns in amyotrophic lateral sclerosis - a scoping review.

Authors:  Anke Erdmann; Celia Spoden; Irene Hirschberg; Gerald Neitzke
Journal:  Palliat Care Soc Pract       Date:  2022-03-15

Review 5.  Advance Care Planning in Neurodegenerative Disorders: A Scoping Review.

Authors:  Andrea Giordano; Ludovica De Panfilis; Marta Perin; Laura Servidio; Marta Cascioli; Maria Grazia Grasso; Alessandra Lugaresi; Eugenio Pucci; Simone Veronese; Alessandra Solari
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.